ProShare Advisors
DYN icon

ProShare Advisors’s Dyne Therapeutics DYN Stock Holding History

ProShare Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$517K Sell
23,283
-3,400
-13% -$63.2K ﹤0.01% 1071
2026
Q1 		$484K Sell
26,683
-2,243
-8% -$38.7K ﹤0.01% 1087
2025
Q4 		$566K Buy
28,926
+5,185
+22% +$98.2K ﹤0.01% 1069
2025
Q3 		$300K Buy
23,741
+251
+1% +$2.86K ﹤0.01% 1420
2025
Q2 		$224K Buy
23,490
+294
+1% +$3.24K ﹤0.01% 1651
2025
Q1 		$243K Sell
23,196
-4,848
-17% -$69.3K ﹤0.01% 1558
2024
Q4 		$661K Buy
28,044
+6,862
+32% +$203K ﹤0.01% 1113
2024
Q3 		$761K Buy
21,182
+6,012
+40% +$239K ﹤0.01% 898
2024
Q2 		$535K Sell
15,170
-1,137
-7% -$33K ﹤0.01% 940
2024
Q1 		$463K Buy
16,307
+5,028
+45% +$114K ﹤0.01% 1137
2023
Q4 		$150K Buy
+11,279
New +$110K ﹤0.01% 1708
2022
Q2 		– Sell
-10,966
Closed -$105K – 1886
2022
Q1 		$105K Sell
10,966
-2,853
-21% -$24.3K ﹤0.01% 2019
2021
Q4 		$163K Buy
+13,819
New +$194K ﹤0.01% 2097

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ProShare Advisors's DYN Position: Q2 2026 in Review

ProShare Advisors reduced its Dyne Therapeutics (DYN) stake by 13% in Q2 2026, selling an estimated $63.2K and leaving 23,283 shares worth $517K. The position accounts for ﹤0.01% of the portfolio, ranked #1071.

ProShare Advisors first reported a position in DYN in Q4 2021 and has held it in 13 quarters since. The position peaked at $761K in Q3 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • ProShare Advisors held 23,283 shares of Dyne Therapeutics worth $517K as of Q2 2026.
  • ProShare Advisors sold 3,400 Dyne Therapeutics shares in Q2 2026, an estimated $63.2K.
  • Dyne Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1071 holding.
  • ProShare Advisors first reported a position in Dyne Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • ProShare Advisors's Dyne Therapeutics position peaked at $761K in Q3 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.